Analytical Data
-
Gene name
CYP2D6
- Application
-
Alternative Names
CYP2D; P450C2D; CPD6; CYP2DL1; P450-DB1; Cytochrome P450 Family 2 Subfamily D Polypeptide 6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10635
-
Expression Region
Leu236~Gln472
-
Molecular Weight
27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP2D6, a member of the cytochrome P450 superfamily, plays a crucial role in the metabolism of roughly 25% of all clinically used drugs, including antidepressants, antipsychotics, and opioids. Its polymorphic nature leads to significant interindividual variability in enzyme activity, categorizing individuals into poor, intermediate, extensive, and ultra-rapid metabolizers. Variations in CYP2D6 activity can result in altered drug efficacy and increased risk of adverse drug reactions. Given the importance of personalized medicine, understanding the functional implications of CYP2D6 polymorphisms is vital for optimizing drug therapy. Research on recombinant CYP2D6 proteins allows scientists to study these variations systematically, facilitating the assessment of enzyme kinetics, interactions with substrates, and the influence of genetic variants on drug metabolism. Such studies are instrumental in guiding pharmacogenetic testing, enhancing therapeutic efficacy, and minimizing adverse effects in patients. The recombinant production of CYP2D6 also supports the development of novel therapeutic agents and the evaluation of drug-drug interactions, thus bridging the gap between molecular biology and clinical applications.
